Urovant Sciences Ltd. (UROV) Stock: Here’s Why It’s Gaining

0

Urovant Sciences Ltd. (UROV) is working its way for to the top in the market today. The company, focused in the biotechnology sector, is presently priced at $[Price] after climbing [Change] so far in today’s session. In terms of biotechnology stocks, there are several aspects that have the ability to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories surrounding UROV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 04:09PM Here’s Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
08:00AM Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Mar-18-19 04:05PM Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
Mar-07-19 08:00AM Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
Mar-06-19 08:00AM Urovant Sciences Appoints James Robinson to its Board of Directors

Nonetheless, when making an investing decision, investors should take a look at far more than news, especially in the speculative biotech industry. Here’s what’s happening with Urovant Sciences Ltd..

Performance Trends That We’ve Seen From UROV

Although a move toward the top in a single session, like the gain that we’re seeing from Urovant Sciences Ltd. may cause excitement in some investors, that by itself should not be the basis of a decision to, or not to, buy a company’s stock. It is generally a good idea to dig into trends experienced by the stock further out than a single trading session. When it comes to UROV, below are the trends that we’ve seen:

  • Past 5 Sessions – In the last 7 days, UROV has generated a change in value that amounts to [Perf Week].
  • Past Month – The monthly performance from Urovant Sciences Ltd. works out to [Perf Month].
  • Past Three Months – In the last three months, the company has produced a return of [Perf Quarter]
  • Past Six Months – Throughout the previous six months, investors have seen a performance of [Perf Half Y] from the stock.
  • Year To Date – Since the open of this year UROV has resulted in a return on investment of [Perf YTD].
  • Full Year – Lastly, over the past full year, we have seen a change of [Perf Year] out of UROV. Over this period of time, the stock has traded at a high of [52W High] and a low price of [52W Low].

Ratios To Watch

Looking at various ratios having to do with a company can give prospective investors a look of how risky and/or potentially profitable a an investment option might be. Below are some of the important ratios to consider when looking at UROV.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the level of short interest. The higher this short ratio, the more investors are expecting that the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, as it relates to Urovant Sciences Ltd., it’s short ratio comes to [Short Ratio].

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure whether or not a company can cover its debts when they mature based on current assets or quick assets. In the biotech industry, companies are heavily reliant on continued support from investors, the current and quick ratios can look damning. Nonetheless, some gems in the biotechnology space come with positive current and quick ratios. In terms of UROV, the quick and current ratios total up to [Quick Ratio] and [Current Ratio] respectively.  

Book To Share Value – The book to share value compares the value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio comes in at [Book/sh].

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to consider. In this case, the cash to share value works out to [Cash/sh].

How Analysts Feel About Urovant Sciences Ltd.

Although it’s not a smart idea to blindly follow the opinions of analysts, it is a smart idea to use their thoughts in order to validate your own opinions when it comes to making an investment decision in the biotechnology sector. Below you’ll find the most recent moves that we have seen from analysts with regard to UROV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 Initiated SunTrust Buy $24
Mar-11-19 Initiated H.C. Wainwright Buy $28
Oct-22-18 Initiated JP Morgan Overweight $21
Oct-22-18 Initiated Jefferies Buy $19

What Are Big Money Players Doing With Urovant Sciences Ltd.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in UROV, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors own [Inst Own] of Urovant Sciences Ltd.. However, it’s important to consider that the ownership held by institutions has seen a move in the amount of [Inst Trans] over the last 3 months.
  • Insiders – As far as insiders go, members of the management team and others close to UROV currently own [Insider Own] of Urovant Sciences Ltd.. Their ownership of the company has changed by [Insider Trans] over the last quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are [Shs Outstand] shares of Urovant Sciences Ltd. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, UROV has a float of [Shs Float].

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to UROV, the short percent of the float is [Short Float].

What We’ve Seen In Financial Results

What have ween seen from UROV in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – At the moment, Wall St. analysts are expecting that UROV will generate earnings per diluted share in the amount of [EPS next Y], with [EPS next Q] being reported in the earnings announcement for the current quarter. Although this is not based on earnings, since we are talking on the topic of Wall St. analysts, Urovant Sciences Ltd. is presently graded as a [Recom] when rated on a scale from 1 to 5 where 1 is the worst possible Wall Street analyst rating and 5 is the best possible.
  • 5-Year Sales – In the past half decade, Urovant Sciences Ltd. has generated a movement in revenue in the amount of [Sales past 5Y]. Earnings per share through the last 5 years have experienced a change of [EPS past 5Y].
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is generally explained in today’s society, the company has seen a earnings change by [EPS Q/Q]. Urovant Sciences Ltd. has also moved the needle when it comes to revenue that comes to a total of [Sales Q/Q].

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was made by a human and human beings actually play an important part in my ability to learn. Sure, I can look through social trends and other publicly available information, but I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here